FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,988,728 | -54.4% | 4,711,664 | +2.4% | 0.01% | -54.5% |
Q2 2023 | $21,893,330 | +29.5% | 4,599,439 | +55.1% | 0.02% | +22.2% |
Q1 2023 | $16,901,880 | +549.5% | 2,965,242 | +1049.7% | 0.02% | +500.0% |
Q4 2022 | $2,602,443 | +34.2% | 257,923 | +415.8% | 0.00% | +50.0% |
Q1 2022 | $1,939,000 | +83.6% | 50,000 | +180.6% | 0.00% | +100.0% |
Q3 2021 | $1,056,000 | -85.4% | 17,821 | -78.7% | 0.00% | -83.3% |
Q2 2021 | $7,251,000 | -71.3% | 83,548 | -72.7% | 0.01% | -75.0% |
Q1 2021 | $25,249,000 | -29.9% | 306,238 | -22.7% | 0.02% | -25.0% |
Q4 2020 | $36,022,000 | +71.2% | 396,157 | -24.7% | 0.03% | +45.5% |
Q3 2020 | $21,037,000 | +36.0% | 526,327 | +16.7% | 0.02% | +22.2% |
Q2 2020 | $15,472,000 | +65.4% | 450,960 | +7.1% | 0.02% | +20.0% |
Q1 2020 | $9,355,000 | +350.0% | 421,201 | +296.4% | 0.02% | +650.0% |
Q4 2019 | $2,079,000 | +670.0% | 106,252 | +697.6% | 0.00% | – |
Q2 2019 | $270,000 | -24.8% | 13,322 | -63.8% | 0.00% | – |
Q1 2018 | $359,000 | – | 36,796 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |